Premium
Zymeworks Inc (ZYME)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-01-12 | Mr. Mark HollywoodExec. VP & COO | 11,55k | 0,00 | Derivative Exercise and Retained Stock | - | 132,91k | 9,51% |
| 2026-01-12 | Mr. Mark HollywoodExec. VP & COO | -6,12k | 138,76k | Derivative Exercise and Sale | 22,67 | 132,91k | - |
| 2026-01-12 | Dr. Jeffrey T. L. SmithInitié | 8,36k | 0,00 | Derivative Exercise and Retained Stock | - | 26,71k | 45,53% |
| 2026-01-12 | Dr. Jeffrey T. L. SmithInitié | -9,31k | 211,09k | Derivative Exercise and Sale | 22,67 | 26,71k | - |
| 2026-01-12 | Dr. Paul A. MooreChief Scientific Officer | 8,11k | 0,00 | Derivative Exercise and Retained Stock | - | 48,50k | 20,07% |
| 2026-01-12 | Dr. Paul A. MooreChief Scientific Officer | -9,56k | 216,76k | Derivative Exercise and Sale | 22,67 | 48,50k | - |
| 2026-01-12 | Mr. Kenneth H. GalbraithChairman of the Board, CEO & President | 33,58k | 0,00 | Derivative Exercise and Retained Stock | - | 226,84k | 17,37% |
| 2026-01-12 | Mr. Kenneth H. GalbraithChairman of the Board, CEO & President | -30,42k | 689,82k | Derivative Exercise and Sale | 22,67 | 226,84k | - |
| 2026-01-05 | Dr. Jeffrey T. L. SmithInitié | 9,46k | 0,00 | Derivative Exercise and Retained Stock | - | 18,35k | 106,43% |
| 2026-01-05 | Dr. Jeffrey T. L. SmithInitié | -10,54k | 264,47k | Derivative Exercise and Sale | 25,10 | 18,35k | - |
| 2026-01-05 | Mr. Kenneth H. GalbraithChairman of the Board, CEO & President | 59,99k | 0,00 | Derivative Exercise and Retained Stock | - | 193,27k | 45,01% |
| 2026-01-05 | Mr. Kenneth H. GalbraithChairman of the Board, CEO & President | -54,34k | 1,36M | Derivative Exercise and Sale | 25,10 | 193,27k | - |
| 2026-01-05 | Dr. Paul A. MooreChief Scientific Officer | 17,06k | 0,00 | Derivative Exercise and Retained Stock | - | 40,39k | 73,11% |
| 2026-01-05 | Dr. Paul A. MooreChief Scientific Officer | -20,11k | 504,70k | Derivative Exercise and Sale | 25,10 | 40,39k | - |
| 2025-12-22 | Mr. Kenneth H. GalbraithChairman of the Board, CEO & President | 52,47k | 0,00 | Derivative Exercise and Retained Stock | - | 133,28k | 64,94% |
| 2025-12-22 | Mr. Kenneth H. GalbraithChairman of the Board, CEO & President | -47,53k | 1,28M | Derivative Exercise and Sale | 27,02 | 133,28k | - |
| 2025-06-26 | EcoR1 Capital, LLCSociété | 4,82M | 481,85 | Derivative Exercise and Retained Stock | 0,00 | 21,58M | 28,74% |
| 2025-06-26 | EcoR1 Capital, LLCSociété | 5,09M | 508,64 | Derivative Exercise and Retained Stock | 0,00 | 22,97M | 28,44% |
| 2025-06-26 | EcoR1 Capital, LLCSociété | -41,00 | 521,11 | Derivative Exercise and Sale | 0,00 - 12,71 | 22,97M | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
